Alsevalimab Biosimilar - Research Grade

Human

VTCN1

>1mg/ml

IgG1 - kappa

CHO Cells

Emiltatug Biosimilar - Research Grade (ICH5519), Puxitatug Biosimilar - Research Grade (ICH5793)

https://www.imgt.org/mAb-DB/

ICH3002

Q7Z7D3

79679

Blue ice

ICH5339 is a research-grade biosimilar of alsevalimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. Alsevalimab (originally developed as FPA150) is a fully human, afucosylated IgG1 kappa monoclonal antibody directed against B7-H4 (VTCN1), an immune checkpoint ligand of the B7 family that is over-expressed on many solid tumors. This biosimilar reproduces the target specificity of the originator and is intended as a tool for in-vitro and functional characterization of B7-H4 biology rather than for clinical use. Because the molecule is afucosylated, it is designed to engage Fc gamma receptor IIIa with enhanced affinity, which underlies the ADCC-focused mechanism attributed to the originator; investigators studying effector function should keep this glycoengineering feature in mind. The product is manufactured to a research-grade endotoxin specification (less than 1 EU/mg) and offered in bulk milligram-to-gram quantities, making it suitable for binding, blockade, and effector-function assays as well as for use as a reference or control reagent. It is not a clinical drug and should not be used for therapeutic or diagnostic purposes. B7-H4, encoded by VTCN1 (UniProt Q7Z7D3), is a type I transmembrane glycoprotein of the B7 immune-costimulatory family with IgV and IgC ectodomains. It acts as a negative regulator of T-cell responses: engagement of its still incompletely defined receptor on T cells delivers an inhibitory signal that suppresses proliferation, cell-cycle progression, and IL-2 production. Under physiological conditions B7-H4 expression is tightly restricted, but it is aberrantly upregulated across many solid tumors, including breast, ovarian, and lung carcinomas, where high expression correlates with poor prognosis and an immunosuppressive microenvironment. This tumor-selective over-expression, combined with its checkpoint activity, makes B7-H4 an attractive oncology target and the rationale for antibodies such as alsevalimab that combine checkpoint blockade with afucosylation-driven ADCC against B7-H4-positive tumor cells.

B7 homolog 4, B7-H4, B7h.5, Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, V-set domain-containing T-cell activation inhibitor 1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Alsevalimab (anti-VTCN1) Biosimilar

Q: Is the Alsevalimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Alsevalimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Alsevalimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Alsevalimab that binds VTCN1.